FYJ-195: Potency Data for a FLT3 Inhibitor Against AML Resistance Mutations

A dataset from figshare describes the biochemical and in vivo evaluation of FYJ-195, a novel FLT3 inhibitor for acute myeloid leukemia. Jin Yang published the data on May 23, 2026. It includes IC50 values for resistant FLT3 mutants and tumor growth inhibition metrics from xenograft models.

Use Cases

• Train predictive models for drug potency based on IC50 values against specific FLT3 mutations.
• Benchmark new FLT3 inhibitors against the reported activity of FYJ-195 on D835V/Y and F691L mutants.
• Analyze structure-activity relationships for type II FLT3 inhibitors based on the described optimization from SILA-123.

Strengths

• Reports specific, single-digit nanomolar IC50 values (e.g., 9.09 nM against FLT3-ITD-F691L).
• Includes in vivo efficacy metrics, such as 125% tumor regression in an MV4-11 xenograft model.
• Data is focused on overcoming specific, clinically relevant resistance mutations (F691L, D835V/Y).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (349.0 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains results from structure-guided drug optimization, biochemical assays, and animal studies.

Freshness

Last updated 2026-05-23 13:35:01; freshness should be verified.